The Tumor Stroma: Biology and Therapeutics First Edition PDF

1. The Tumor Stroma: Key Component of Solid Tumors 1
Jai Prakash 1.1 Normal Stroma Versus Tumor Stroma 1
1.2 Cellular Composition of the Tumor Stroma
and Its Interactions 3
1.3 Non-cellular Composition of the Tumor
Stroma and Its Interactions 5
1.4 Tumor Stroma Architecture and Heterogeneity 7
1.5 Pathological Significance of the Tumor Stroma 8
1.6 Therapeutic Opportunities in the Tumor Stroma 9
2. Cancer-Associated Fibroblasts: Building Blocks
of the Tumor Stroma 17
Ahmed M. R. H. Mostafa, Alaa M. Ramadan, Arne Östman, and Jai Prakash 2.1 Cancer-Associated Fibroblasts 17
2.2 Molecular Characteristics of CAFs 19
2.2.1 Transcriptomic Regulation 19
2.2.2 Epigenetic Regulation 20
2.3 Origin and Heterogeneity of CAFs 21
2.3.1 CAFs in Breast Cancer 22
2.3.2 CAFs in Lung Cancer 24
2.3.3 CAFs in Pancreatic Cancer 25
2.4 Functions of CAFs in Cancer 26
2.4.1 Role of CAFs in Cancer Progression 26
2.4.2 Role of CAFs in Cancer Metastasis 27
2.4.3 Role of CAFs in Chemoresistance 28
2.4.4 Role of CAFs in Building Stroma and
ECM Remodeling 29
2.4.5 Role of CAFs in Tumor Metabolism 29
2.4.6 Role of CAFs in Inducing
Immunosuppression 30…
The Tumor Stroma: Biology and Therapeutics First Edition PDF Ebook

Jai Prakash, professor of targeted therapeutics and nanomedicine at the University of Twente in the Netherlands, is a pharmaceutical and bioentrepreneurial scientist with a background in developing novel targeted (nano)therapeutics against fibrosis and tumor stroma. He obtained his PhD (cum laude) in 2006 from the University of Groningen, the Netherlands, and thereafter worked as vice president at BiOrion Technologies BV, the Netherlands, assistant professor at Karolinska Institutet, Sweden, and tenure track professor at the University of Twente. He is a founder and CSO of a spin-off company ScarTec Therapeutics BV, the Netherlands, which develops novel therapeutics against fibrosis and cancer. He holds several academic positions, including president of BeNeLux and France local chapter for the Controlled Release Society, and editorial positions for many journals. He is expert referee for more than 20 grant agencies worldwide. His current research focuses on designing targeting technologies to modulate the tumor microenvironment to intervene into the fibrotic and inflammatory crosstalk between tumor cells and stromal cells.